Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes
Hepatocellular carcinoma (HCC) is a highly aggressive and lethal cancer. It is typically asymptomatic at the early stage, with only 10%–20% of HCC patients being diagnosed early enough for appropriate surgical treatment. The delayed diagnosis of HCC is associated with limited treatment options and m...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2013/759057 |
id |
doaj-467850c2d686470a8c92c5e7b003bcff |
---|---|
record_format |
Article |
spelling |
doaj-467850c2d686470a8c92c5e7b003bcff2020-11-24T22:54:22ZengHindawi LimitedBioMed Research International2314-61332314-61412013-01-01201310.1155/2013/759057759057Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody ProbesPing Zhao0Xiaoyang Yang1Shibo Qi2Hongguang Liu3Han Jiang4Susan Hoppmann5Qizhen Cao6Mei-Sze Chua7Samuel K. So8Zhen Cheng9Department of Digestive, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130033, ChinaDepartment of Surgery, Asian Liver Center, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USADepartment of Radiology and Bio-X Program, Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Center, P095, Stanford University, Stanford, CA 94305, USADepartment of Radiology and Bio-X Program, Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Center, P095, Stanford University, Stanford, CA 94305, USADepartment of Radiology and Bio-X Program, Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Center, P095, Stanford University, Stanford, CA 94305, USADepartment of Radiology and Bio-X Program, Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Center, P095, Stanford University, Stanford, CA 94305, USADepartment of Radiology and Bio-X Program, Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Center, P095, Stanford University, Stanford, CA 94305, USADepartment of Surgery, Asian Liver Center, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USADepartment of Surgery, Asian Liver Center, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USADepartment of Radiology and Bio-X Program, Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Center, P095, Stanford University, Stanford, CA 94305, USAHepatocellular carcinoma (HCC) is a highly aggressive and lethal cancer. It is typically asymptomatic at the early stage, with only 10%–20% of HCC patients being diagnosed early enough for appropriate surgical treatment. The delayed diagnosis of HCC is associated with limited treatment options and much lower survival rates. Therefore, the early and accurate detection of HCC is crucial to improve its currently dismal prognosis. The epidermal growth factor receptor (EGFR) has been reported to be involved in HCC tumorigenesis and to represent an attractive target for HCC imaging and therapy. In this study, an affibody molecule, Ac-Cys-ZEGFR:1907, targeting the extracellular domain of EGFR, was used for the first time to assess its potential to detect HCC xenografts. By evaluating radio- or fluorescent-labeled Ac-Cys-ZEGFR:1907 as a probe for positron emission tomography (PET) or optical imaging of HCC, subcutaneous EGFR-positive HCC xenografts were found to be successfully imaged by the PET probe. Thus, affibody-based PET imaging of EGFR provides a promising approach for detecting HCC in vivo.http://dx.doi.org/10.1155/2013/759057 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ping Zhao Xiaoyang Yang Shibo Qi Hongguang Liu Han Jiang Susan Hoppmann Qizhen Cao Mei-Sze Chua Samuel K. So Zhen Cheng |
spellingShingle |
Ping Zhao Xiaoyang Yang Shibo Qi Hongguang Liu Han Jiang Susan Hoppmann Qizhen Cao Mei-Sze Chua Samuel K. So Zhen Cheng Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes BioMed Research International |
author_facet |
Ping Zhao Xiaoyang Yang Shibo Qi Hongguang Liu Han Jiang Susan Hoppmann Qizhen Cao Mei-Sze Chua Samuel K. So Zhen Cheng |
author_sort |
Ping Zhao |
title |
Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes |
title_short |
Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes |
title_full |
Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes |
title_fullStr |
Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes |
title_full_unstemmed |
Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes |
title_sort |
molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2013-01-01 |
description |
Hepatocellular carcinoma (HCC) is a highly aggressive and lethal cancer. It is typically asymptomatic at the early stage, with only 10%–20% of HCC patients being diagnosed early enough for appropriate surgical treatment. The delayed diagnosis of HCC is associated with limited treatment options and much lower survival rates. Therefore, the early and accurate detection of HCC is crucial to improve its currently dismal prognosis. The epidermal growth factor receptor (EGFR) has been reported to be involved in HCC tumorigenesis and to represent an attractive target for HCC imaging and therapy. In this study, an affibody molecule, Ac-Cys-ZEGFR:1907, targeting the extracellular domain of EGFR, was used for the first time to assess its potential to detect HCC xenografts. By evaluating radio- or fluorescent-labeled Ac-Cys-ZEGFR:1907 as a probe for positron emission tomography (PET) or optical imaging of HCC, subcutaneous EGFR-positive HCC xenografts were found to be successfully imaged by the PET probe. Thus, affibody-based PET imaging of EGFR provides a promising approach for detecting HCC in vivo. |
url |
http://dx.doi.org/10.1155/2013/759057 |
work_keys_str_mv |
AT pingzhao molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT xiaoyangyang molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT shiboqi molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT hongguangliu molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT hanjiang molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT susanhoppmann molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT qizhencao molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT meiszechua molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT samuelkso molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes AT zhencheng molecularimagingofhepatocellularcarcinomaxenograftswithepidermalgrowthfactorreceptortargetedaffibodyprobes |
_version_ |
1725660299139219456 |